Peer-reviewed veterinary case report
Bexagliflozin for poorly controlled diabetes in cats
By Benedict, Suzanne L et al.·Published in Canadian journal of veterinary research = Revue canadienne de recherche veterinaire·2022·Cummings School of Veterinary Medicine (Benedict), United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Evaluation of bexagliflozin in cats with poorly regulated diabetes mellitus.
- Species:
- cat
Plain-English summary
Five cats with poorly controlled diabetes were given a new medication called bexagliflozin to see if it could help manage their blood sugar levels better. Over four weeks, the cats showed a significant decrease in their need for insulin, with two of them even stopping insulin altogether. Their blood glucose levels improved, and while one cat didn't show a significant change in a specific blood marker, the overall results were positive. None of the cats experienced low blood sugar, and any side effects were mild. This medication appears to be a helpful option for managing diabetes in cats.
People also search for: cat diabetes treatment · bexagliflozin for cats · poorly controlled diabetes in cats · insulin for diabetic cats · managing cat blood sugar levels
Abstract
The aim of this study was to investigate the effect of bexagliflozin on glycemic control in poorly regulated diabetic cats and to evaluate for adverse events associated with this medication. Sodium-glucose cotransporter 2 inhibitors are a newer class of drugs used in the management of humans with type 2 diabetes mellitus. The objective of this study was to evaluate the effect of the orally administered drug, bexagliflozin in a group of poorly regulated diabetic cats over a 4-week study period. Five client-owned cats with poorly controlled diabetes mellitus receiving insulin therapy were enrolled. Bexagliflozin was administered once daily. Serum fructosamine, serum biochemistry profile, and 10-hour blood glucose curves were assessed at baseline (Day 0), Day 14, and Day 28. All cats had a significant reduction in insulin dose requirement (= 0.015) and insulin was discontinued in 2 cats. There was a significant decrease in blood glucose concentration obtained from blood glucose concentration curves during the study period (= 0.022). Serum fructosamine decreased in 4 of the 5 cats with a median decrease of 152 μmol/L (range: 103 to 241 μmol/L), which was not statistically significant (= 0.117). No cats had any documented episodes of hypoglycemia. Adverse effects were mild. The addition of bexagliflozin significantly improved diabetic management in this group of cats.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/34975223/